Table 1 Baseline characteristics of individuals by cohort.
From: Machine learning based early warning system enables accurate mortality risk prediction for COVID-19
SFT cohort | SFV cohort | OV cohort | CHWH cohort | |
|---|---|---|---|---|
Characteristics | (n = 621) | (n = 622) | (n = 801) | (n = 116) |
Age | 62 (51–71) | 63 (51–70) | 63 (50–70) | 62.5 (55–72) |
Sex | ||||
Female | 306 (49.3%) | 311 (50.0%) | 427 (53.3%) | 53 (45.7%) |
Male | 315 (50.7%) | 311 (50.0%) | 374 (46.7%) | 63 (54.3%) |
Comorbidity number | 1 (0–2) | 1 (0–2) | 1 (0–2) | 2 (1–3) |
Comorbidity | ||||
Hypertension | 245 (39.5%) | 244 (39.2%) | 321 (40.3%) | 43 (37.1%) |
Diabetes | 110 (17.7%) | 110 (17.7%) | 121 (15.2%) | 16 (13.8%) |
CHD | 72 (11.6%) | 59 (9.5%) | 68 (8.5%) | 16 (13.8%) |
CLD | 26 (4.2%) | 19 (3.1%) | 33 (4.1%) | 7 (6.0%) |
Tumor | 22 (3.5%) | 21 (3.4%) | 20 (2.5%) | 51 (44.0%) |
HBV | 16 (2.6%) | 13 (2.1%) | 24 (3.0%) | 1 (1.0%) |
CKD | 13 (2.1%) | 8 (1.3%) | 11 (1.4%) | 1 (0.9%) |
COPD | 4 (0.6%) | 7 (1.1%) | 7 (0.9%) | 1 (0.9%) |
Fever | 533 (86.0%) | 527 (84.9%) | 584 (73.0%) | 71 (61.2%) |
Temp (max) ≥ 39 °C | 169 (27.4%) | 194 (31.5%) | 158 (19.8%) | 16 (14.2%) |
Cough | 450 (72.6%) | 436 (70.2%) | 601 (75.1%) | 63 (54.3%) |
Dyspnea | 313 (50.5%) | 283 (45.6%) | 274 (34.2%) | 37 (31.9%) |
Sputum | 233 (37.6%) | 228 (36.7%) | 344 (43.0%) | 32 (27.6%) |
Fatigue | 253 (40.8%) | 233 (37.5%) | 250 (31.2%) | 43 (37.1%) |
Diarrhea | 186 (30.0%) | 167 (26.9%) | 135 (16.9%) | 9 (7.8%) |
Myalgia | 133 (21.5%) | 144 (23.2%) | 129 (16.1%) | 20 (17.2%) |
Vomiting | 30 (4.8%) | 31 (5.0%) | 32 (4.0%) | 3 (2.6%) |
Conscious at admission | 595 (95.8%) | 600 (96.5%) | 786 (98.1%) | 79 (68.1%) |
Respiratory rate, per min | 20 (20–22) | 21 (20–24) | 21 (20–24) | 21 (20–24) |
MAP, mmHg | 96.7 (88.7–104.7) | 97.2 (89.7–105.6) | 96.3 (87.7–106.7) | 93.3 (86.9–101.5) |
SpO2, % | 95 (91–97) | 95 (91–97) | 96 (94–97) | 95.5 (93–97.3) |
Vital status | ||||
Death | 86 (13.8%) | 89 (14.3%) | 60 (7.5%) | 19 (16.4%) |
Discharge | 535 (86.2%) | 533 (85.7%) | 741 (92.5%) | 97 (83.6%) |
Follow-up, days | 23 (15–30) | 21 (15–29) | 19 (14–26) | 17 (12–24) |
